search icon
  • Print
  • ShareThis
  • Text Size

RSS Feed Print Category View
Merck Unveils Interim Phase II Results
tkim@idsociety.org
Posted: Thursday, April 10, 2014 1:46 PM
Joined: 2/20/2013
Posts: 39


"Merck may be late to the blockbuster party with its new hepatitis C drugs, but the pharma giant is moving fast with a top contender boasting high cure rates.

Merck unveiled interim Phase II results for an oral combination of MK-5172, its NS3/4A protease inhibitor, and MK-8742, an NS5A, among patients with chronic HCV genotype 1 infection. After 12 weeks of therapy 42 of 43 patients--98%--demonstrated a sustained viral response. The combination plus ribavirin hit a 94% cure rate. And the drugs did it without any injections of interferon, which is widely hated by patients."


To read more, please visit: http://www.fiercebiotech.com/story/watch-out-gilead-merck-mounting-hep-c-combo-comeback/2014-04-10#ixzz2yVTcmBPY


 

| HIVMA | Contact Us

© Copyright IDSA 2014 Infectious Diseases Society of America

Full Site Mobile Site